LifeCanvas Technologies is a tissue clearing and light-sheet imaging company in Cambridge, Massachusetts, founded by Kwanghun Chung of the Massachusetts Institute of Technology.[S2][S3] It is not a general nonclinical contract research organization, and reading it as one would lead a sponsor to the wrong scope. The company sells instruments, reagents and analysis software for making whole organs optically transparent and imaging them intact, and it also runs those workflows as a service on tissue that clients send in.[S1][S4][S9] The service pages are explicit about the handoff: the client ships fixed samples.[S4][S5] For the services described on the reviewed pages, clients ship fixed samples; confirm separately where dosing, in-life observation and necropsy will be performed. LifeCanvas describes three-dimensional whole-organ imaging and analysis of client-supplied fixed tissue.
The contract services are whole-organ tissue clearing, immunolabeling, imaging and analysis, performed on paraformaldehyde-fixed material supplied by the client.[S4][S8] No service line was found for in-life efficacy dosing, GLP toxicology, safety pharmacology, drug metabolism and pharmacokinetics, bioanalysis, or standalone histopathology reporting, and no statement was found describing animal housing at the company own site.[S1][S4] A sponsor would therefore place a study with an in vivo laboratory and send the fixed tissue here, or run the in-life phase internally. Where a program already has a source of tissue, sponsors using this workflow should confirm sample transfer requirements, responsibilities and timelines with both providers.
Two of the named services map directly onto questions that come up in nonclinical development. The first is three-dimensional mapping of adeno-associated virus vector biodistribution across whole organs, delivered as heat maps and quantitative plots through a web portal.[S5] The company offers three-dimensional AAV vector biodistribution mapping across whole organs, delivering heat maps and quantitative plots through a web portal. The second is brain-wide mapping of c-FOS positive cells, registered to a reference brain atlas, used to describe where neural activity changed.[S6] A third service quantifies amyloid beta plaque and alpha-synuclein aggregate burden in intact brains from neurodegenerative disease models.[S7] These are descriptive readouts of what happened in the tissue supplied; they do not by themselves establish efficacy, and the company does not present them as doing so.
The same workflows are sold as products for laboratories that prefer to run them internally. SHIELD is a preservation chemistry that the company states protects endogenous fluorescence, protein antigenicity, nucleic acids and tissue architecture before clearing.[S9] SmartBatch+ is an instrument that performs active clearing and immunolabeling, with stated throughput of up to twelve whole mouse brains in about a day, or two whole rat brains in three to four days.[S9] SmartSPIM is a light-sheet microscope stated to image a mouse brain hemisphere in under thirty minutes at a voxel size of roughly 1.8 by 1.8 by 4 micrometers.[S10] DALISPIM, announced in October 2025, is an open-top inverted design that images samples directly in multiwell plates, dishes and organ-on-a-chip devices.[S12] MegaSPIM is listed in the same product family, but the page reviewed did not carry specifications distinct from the family description, so it is named here without detail.[S9] SmartAnalytics provides automated registration to mouse and rat brain atlases with pretrained models for several markers.[S11]
No GLP claim was found on the pages reviewed, and no reference to AAALAC accreditation, USDA registration, an OLAW Animal Welfare Assurance, or an Institutional Animal Care and Use Committee was found on the pages reviewed.[S1][S2][S4] That is an absence in those pages, not a finding about the status of the company: the accreditations above relate to the care and use of live animals, and the company describes receiving tissue that has already been fixed.[S4] AAALAC International accreditation is a voluntary evaluation of an institution's animal care and use program, re-evaluated every three years,[R3] and USDA registration and an OLAW Animal Welfare Assurance relate to the Animal Welfare Act and the PHS Policy respectively;[R4][R5] none of these establishes GLP compliance, which applies to individual studies.[R2] FDA does not approve or certify laboratories; registration with FDA does not denote approval.[R6] A sponsor intending to use imaging data in a regulatory submission should establish where the study record begins, since the GLP status of a study is determined for the study as a whole under the applicable regulation, including work placed with a subcontractor.[R2] No ISO, clinical laboratory or other quality system certification was found on the site either.
| Name | LifeCanvas Technologies; no legal entity suffix is given on the site[S1] |
|---|---|
| Headquarters | 1035 Cambridge Street, Suite 16C, Cambridge, MA 02141, United States[S3] |
| Other office | Seoul, Republic of Korea[S3] |
| Founder | Kwanghun Chung, Massachusetts Institute of Technology[S2] |
| Founded | Not stated on the site |
| Ownership | Not stated on the site; not stated on the site |
| Employees and revenue | Not published |
| Contract services | Tissue clearing; 3D AAV biodistribution mapping; brain-wide c-FOS mapping; neurodegenerative disease pathology mapping; custom multi-target labeling[S4][S5][S6][S7][S8] |
| Sample handling | Clients ship paraformaldehyde-fixed tissue; no animal housing or dosing is described on the site[S4][S5] |
| Products | SHIELD, SmartBatch+, SmartSPIM, MegaSPIM, DALISPIM, SmartAnalytics, EasyIndex[S9] |
| Species and samples | Primarily mouse, also rat; organoids and other organ types for custom work[S8][S10] |
| GLP, AAALAC, USDA, OLAW | No statement found on the site |
| Website | lifecanvastech.com |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.